Helping Brain Tumor Patients Cope With Cognitive Changes

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 10
Volume 9
Issue 10

NEW YORK-The cognitive and behavioral effects of brain tumors and their treatment are often invisible to patients, caregivers, and even clinicians, Robert A. Stern, PhD, said at a Cancer Care, Inc. teleconference for patients and their families. Dr. Stern is director of the Neuropsychology Program, Rhode Island Hospital, and associate professor of psychiatry and neurology, Brown University School of Medicine.

NEW YORK—The cognitive and behavioral effects of brain tumors and their treatment are often invisible to patients, caregivers, and even clinicians, Robert A. Stern, PhD, said at a Cancer Care, Inc. teleconference for patients and their families. Dr. Stern is director of the Neuropsychology Program, Rhode Island Hospital, and associate professor of psychiatry and neurology, Brown University School of Medicine.

He urged patients and caregivers to ask their physicians for referrals to specialists who can evaluate their cognitive and emotional status following treatment for a brain tumor.

The most important thing to realize, he said, is that brain tumors and their treatments, including radiation and chemotherapy, are commonly associated with alterations of cognitive and behavioral functioning.

These may include changes in personality and problems in organization, the ability to juggle more than one thing at a time, concentration, language, abstract thinking, movement, facial expressions, memory, emotional functioning, and how the patient relates to others.

“Often the patients doesn’t complain about any of these difficulties,” Dr. Stern said. “To those who are interacting with the patient, it may seem like denial or some type of defense mechanism, but with brain tumors, the brain damage can cause patients not even to be aware of their neurological problems.”

Without special training and experience in the assessment of these cognitive and behavior changes, a physician may quickly examine all of these areas and still miss the deficits. The fact that the individual is alive, walking, and talking may be considered enough of a success, he said, “but the remaining person is not the same.”

Dr. Stern urged caregivers to ask the patient’s treating physician for a referral to a neuropsychologist for an evaluation. The evaluation, which can take anywhere from 3 to 5 hours, will indicate the relationship between the brain damage and behavior.

Once specific neuropsychological strengths and weaknesses are determined, an individual treatment plan can be developed. The goal of any cognitive rehabilitation treatment, Dr. Stern said, “is to exploit the intact areas of functioning.”

Among those who can provide cognitive rehabilitation are neuropsychologists, occupational therapists, and speech therapists, he said.

Depression and Anxiety

Brain tumor patients may also experience anxiety, aggression, and even delusions or paranoia associated with the brain tumor. Depression in brain tumor patients is often directly related to the damage caused by the tumor and the treatment, Dr. Stern explained.

Neuropsychiatrists—physicians with special training and experience in the psychiatric manifestations of neurological disorders—may treat this type of depression as well as other emotional difficulties arising from brain damage with medication. Neuropsychologists may provide psychotherapy and counseling, as well as cognitive rehabilitation.

Dr. Stern warned that insurance companies, although they may pay for neuropsychological evaluations, may, at first, refuse to pay for cognitive rehabilitation and other forms of therapy. “My recommendation is, don’t give up. Make demands. Ask to speak to a supervisor. Explain that there is no reason why someone should be left without treatment.”

Recent Videos
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.